Therapeutic antibodies for the prevention and treatment of cancer DOI Creative Commons
Mukesh Kumar,

Akansha Jalota,

Ashutosh Kumar

et al.

Journal of Biomedical Science, Journal Year: 2024, Volume and Issue: 31(1)

Published: Jan. 12, 2024

Abstract The developments of antibodies for cancer therapeutics have made remarkable success in recent years. There are multiple factors contributing to the biological molecule including origin antibody, isotype, affinity, avidity and mechanism action. With better understanding progression immune manipulation, recombinant formats used develop therapeutic modalities manipulating cells patients by targeting specific molecules control disease. These been successful minimizing side effects instead caused small or systemic chemotherapy but because developing resistance against these antibodies, combination therapy is thought be best bet patient care. Here, this review, we discussed different aspects affecting their efficacy with some relevant examples most studied approved US FDA.

Language: Английский

Multiple myeloma: signaling pathways and targeted therapy DOI Creative Commons

Qizhong Lu,

Donghui Yang, Hexian Li

et al.

Molecular Biomedicine, Journal Year: 2024, Volume and Issue: 5(1)

Published: July 4, 2024

Abstract Multiple myeloma (MM) is the second most common hematological malignancy of plasma cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and accumulation malignant cells. The pathogenesis MM involves interaction between cells marrow microenvironment through soluble cytokines cell adhesion molecules, which activate various signaling pathways such as PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT, Wnt/β-catenin, NF-κB pathways. Aberrant activation these contributes to proliferation, survival, migration, drug resistance making them attractive targets for therapeutic intervention. Currently, approved drugs targeting in are limited, with many inhibitors inducers still preclinical or clinical research stages. Therapeutic options include non-targeted like alkylating agents, corticosteroids, immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors. Additionally, targeted monoclonal antibodies, chimeric antigen receptor T bispecific T-cell engagers, antibodies being used treatment. Despite significant advancements treatment, disease remains incurable, emphasizing need development novel combined therapies based on emerging theoretical knowledge, technologies, platforms. In this review, we highlight key role progression treatment MM, exploring advances therapy potential treatments offer further insights improving management outcomes.

Language: Английский

Citations

18
Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta‐analysis DOI Creative Commons
Paschalis Karakasis, Eleftheria Lefkou, Konstantinos Pamporis

et al.

European Journal of Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

Clonal haematopoiesis (CH) is recognized as a significant risk factor for various non-haematologic conditions, including cardiovascular diseases. However, recent studies examining its relationship with heart failure (HF) have reported conflicting findings. To address these inconsistencies, the present meta-analysis aimed to evaluate association of CH incidence and clinical outcomes HF. MEDLINE, Cochrane Library Scopus were searched until 12 December 2024. Triple-independent study selection, data extraction quality assessment performed. Evidence was pooled using three-level mixed-effects meta-analyses. Participants (n = 57 755) had significantly greater new-onset HF compared non-CH group (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.12-1.35, p < 0.0001; I2 0%), irrespective prior history coronary artery disease. also correlated higher composite outcome all-cause mortality hospitalization (HHF) in patients established (HR 1.84, CI 1.25-2.70, 0.002; 0%). Specifically, associated 1.95, 1.54-2.47, 3% increase every 1% variant allele fraction. concomitant 56% HHF 1.56, 1.05-2.33, 0.029; 19%). an increased incident worse prognosis individuals affected by These findings highlight potential contribute deeper understanding HF, improve stratification, support more personalized approaches management.

Language: Английский

Citations

2
Immunotherapy: an alternative promising therapeutic approach against cancers DOI Open Access
Sneh Lata Gupta, Srijani Basu, Vijay Soni

et al.

Molecular Biology Reports, Journal Year: 2022, Volume and Issue: 49(10), P. 9903 - 9913

Published: June 27, 2022

Language: Английский

Citations

65
LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation DOI Creative Commons

Eun-Sil Sung,

Minkyung Ko, Ju‐young Won

et al.

Molecular Therapy, Journal Year: 2022, Volume and Issue: 30(8), P. 2800 - 2816

Published: May 6, 2022

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with other checkpoint inhibitors. Lymphocyte-activation gene 3 (LAG-3) is an inhibitory receptor involved in T exhaustion and tumor immune escape. Here, we describe ABL501, a bispecific antibody targeting LAG-3 PD-L1 modulating responses against tumors. ABL501 efficiently inhibits both pathways enhances the activation effector CD4

Language: Английский

Citations

59
Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches DOI Creative Commons
Heinz Laübli, Sam C. Nalle, Daniel Maslyar

et al.

Cancer Immunology Research, Journal Year: 2022, Volume and Issue: 10(12), P. 1423 - 1432

Published: Oct. 20, 2022

The sialic acid-binding immunoglobulin-like lectin (Siglec)-sialic acid immune axis is an evolutionarily conserved immunoregulatory pathway that provides a mechanism for establishing self-recognition and combatting invasive pathogens. Perturbations in the lead to many dysregulated diseases, including autoimmunity, neurodegeneration, allergic conditions, cancer. purpose of this review provide brief overview relationship between Siglecs as they relate human health disease, consider current Siglec-based therapeutics, discuss new therapeutic approaches targeting Siglec-sialic axis, with focus on

Language: Английский

Citations

56
Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance? DOI Open Access

Yefang Lao,

Daoming Shen,

Weili Zhang

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(15), P. 3575 - 3575

Published: July 22, 2022

Immune checkpoint inhibitors (ICIs), antagonists used to remove tumor suppression of immune cells, have been widely in clinical settings. Their high antitumor effect makes them crucial for treating cancer after surgery, radiotherapy, chemotherapy, and targeted therapy. However, with the advent ICIs their use by a large number patients, more data gradually shown that some patients still resistance ICI treatment, which unable benefit from effect. Therefore, it is vital understand drug mechanisms. In this review, we focused on action sites mechanisms different types ICIs. We then listed main possible based recent studies. Finally, proposed current future solutions ICIs, providing theoretical support improving

Language: Английский

Citations

52
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation DOI
Haonan Li, Qiang Luo, Hu Zhang

et al.

Chemical Society Reviews, Journal Year: 2022, Volume and Issue: 52(1), P. 47 - 96

Published: Nov. 25, 2022

This review overviews the landscape of nanomedicine-aided cancer radio-immunotherapy in a “from bench to clinic” manner.

Language: Английский

Citations

47
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? DOI Creative Commons
Dávid Kegyes, Cătălin Constantinescu,

Louise Vrancken

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: June 7, 2022

Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remains incurable disease. Novel immunotherapies, such as CAR T therapy (CAR) bispecific engagers (BiTE), are intensively targeting different surface antigens, BMCA, SLAMF7 (CS1), GPRC5D, FCRH5 or CD38. However, stem transplantation still indispensable in transplant-eligible patients. Studies suggest early use immunotherapy may improve outcomes significantly. In this review, we summarize currently available clinical literature on BiTE MM. Furthermore, will compare these two cell-based immunotherapies discuss potential therapeutic approaches promote development trials, using even bridging therapies transplant.

Language: Английский

Citations

45
Current and emerging therapies for neuroendocrine prostate cancer DOI
Busola R. Alabi, Shiqin Liu, Tanya Stoyanova

et al.

Pharmacology & Therapeutics, Journal Year: 2022, Volume and Issue: 238, P. 108255 - 108255

Published: July 27, 2022

Language: Английский

Citations

41
Modulating T Cell Responses by Targeting CD3 DOI Open Access

Ashwathi Puravankara Menon,

Beatriz Moreno, Daniel Meraviglia-Crivelli

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(4), P. 1189 - 1189

Published: Feb. 13, 2023

Harnessing the immune system to fight cancer has become a reality with clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all patients respond ICB. Thus, there is need modulate through alternative strategies for improving responses The CD3-T cell receptor (TCR) canonical complex on T cells. It provides "first signal" that initiates activation determines specificity response. TCR confers binding whilst CD3 subunits facilitate signal transduction necessary activation. While mechanisms which antigen sensing occur in CD3-TCR are still under debate, recent revelations regarding intricate 3D structure might open possibility modulating its activity by designing targeted drugs tools, including aptamers. In this review, we summarize basis assembly survey preclinical therapeutic tools available function potentiating immunotherapy.

Language: Английский

Citations

41